- Welcome and Introduction (5 min)
- CDK4/6 Inhibitors for Premenopausal and Postmenopausal Women With HR-Positive/HER2-Negative Advanced Breast Cancer – Sara Hurvitz, MD, FACP (30 min)
- Key clinical trial data for abemaciclib, palbociclib, and ribociclib
- Selecting the optimal CDK4/6 inhibitor
- Dosing and adherence
- Monitoring for and managing common toxicities with CDK4/6 inhibitors
- PI3K/AKT/mTOR Inhibitors and Future Directions in HR-Positive/HER2-Negative Advanced Breast Cancer – Sara Tolaney, MD, MPH (15 min)
- Final Thoughts, Panel Discussion, and Audience Question & Answer Session – Sara Hurvitz, MD, FACP, and Sara Tolaney, MD, MPH (10 min)
Date / Time
Sara Hurvitz, MD
Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Sara Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Susan F. Smith Center for Women's Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy Clinical Research
Breast Oncology Program
Dana-Farber Cancer Institute
The goal of this activity is to improve the competence and performance of learners in applying practice-changing clinical data and expert recommendations regarding the use of current and emerging endocrine and targeted therapies in the management of patients with HR-positive/HER2-negative ABC.
This program is intended for oncologists and other healthcare providers who care for patients with breast cancer.
- Evaluate current guidelines and current/emerging clinical trial data on currently approved and emerging endocrine and targeted therapies for HR-positive/HER2-negative ABC to aid in the refinement of current treatment algorithms
- Understand the biologic rationale for therapeutically targeting CDK4/6 and the PI3K/AKT/mTOR pathway and appraise published efficacy/safety data on the use of CDK4/6 inhibitors, PI3K inhibitors, mTOR inhibitors, and emerging strategies for patients with HR-positive/HER2-negative ABC
- Develop strategies to anticipate, monitor, and manage adverse events with currently approved endocrine and targeted therapies for HR-positive/HER2-negative ABC to support quality of life and continuation of treatment
- Identify patients with HR-positive/HER2-negative ABC suitable for enrollment on ongoing clinical studies investigating novel therapies
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.